Therefore, understanding the molecular mechanism for inter-regulation among REP1, mTORC1, and lysosomal degradation pathways would provide an intriguing rationale for targeting for pancreatic cancers with high capacities for lysosomal degradation. Here, CHM is linked to familial pancreatic carcinoma.